- ►diabetesjournals.org RA Noel, DK Braun, RE Patterson, GL Bloomgren - Diabetes Care, 2009 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS We conducted a retrospective cohort study using a
large, geographically diverse US health care claims database. Eligible patients (≥18 years)
were enrolled for at least 12 continuous months (1999–2005), with no incident events of ... Cited by 6 - Related articles - All 3 versions
J Khoo, CK Rayner, KL Jones, M Horowitz - 2009 - pubmedcentral.nih.gov The advent of 'incretin-based therapies' – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors
– which result in improvements in glycemic control comparable to those with existing oral hypoglycemic
agents, and potentially improve cardiovascular and pancreatic β-cell function, represents ... Related articles - All 4 versions
- ►easd.org [PDF] EAM Gale - Diabetologia, 2009 - Springer Drugs for health generate wealth, and wealth drives the diabetes roadshow. Without it, the subsidised
seasonal migrations to our big meetings would grind to a halt, and the KOLs (Key Opinion
Leaders, for the uninitiated) would all be driving a different brand of car. Given that the ... Cited by 1 - Related articles - All 3 versions
JB McGill - jfponline.com Among the treatments available for patients with type 2 diabetes mellitus (T2DM) who do not
achieve or maintain glycemic control with the combination of lifestyle management and metformin
(ie, tier 1/step 1 therapy), 4 other classes of medications are considered preferred ... Related articles - Cached - All 2 versions
J Holst - medscape.com Clinicians, especially primary care providers, are faced with an estimated 20 million Americans
diagnosed with diabetes and approximately 1.5 million new cases each year. Often these patients
have comorbid conditions that only further reduce their long-term heath. The goal of any ... Related articles
JB Buse, J Rosenstock, G Sesti, WE Schmidt, E … - The Lancet, 2009 - Elsevier Mean baseline HbA 1c for the study population was 8·2%. Liraglutide reduced mean HbA 1c
significantly more than did exenatide (−1·12% [SE 0·08] vs −0·79% [0·08]; estimated treatment
difference −0·33; 95% CI −0·47 to −0·18; p<0·0001) and more patients achieved a HbA 1c ... Cited by 18 - Related articles - All 25 versions
MJ Lage, R Fabunmi, KS Boye, DA Misurski - Advances in Therapy, 2009 - Springer Page 1. Adv Ther (2009) 26(2):217-229. DOI 10.1007/s12325-009-0002-0 ORIGINAL
RESEARCH Comparison of Costs among Patients with Type 2 Diabetes Treated with
Exenatide or Sitagliptin Therapy Maureen J. Lage ∙ Rosalind ... Cited by 1 - Related articles - All 2 versions
RE Pratley - Expert Opin. Pharmacother., 2009 - informahealthcare.com Background: Alogliptin is a potent, highly selective dipeptidyl peptidase-4 inhibitor now undergoing
clinical testing to support a new drug application for the treatment of type 2 diabetes.
Objective: To provide an overview of the mechanism by which alogliptin reduces ... Cited by 1 - Related articles - All 7 versions
JA Koehler, LL Baggio, BJ Lamont, S Ali, DJ Drucker - Diabetes, 2009 - glucagon.com Page 1. GLP-1 and experimental murine pancreatitis GLP-1 receptor activation
modulates pancreatitis-associated gene expression but does not modify the
susceptibility to experimental pancreatitis in mice Jacqueline A. Koehler ... Cited by 1 - Related articles - View as HTML - All 4 versions
K Müssig, A Öncü, P Lindauer, A Heininger, H … - The American Journal of …, 2008 - Elsevier We recently assessed the efficacy of a continuous intravenous infusion of GLP-1 on glycemic
control and cardiovascular parameters in patients with type 2 diabetes after CABG and compared
this intervention with a standard insulin treatment regimen. Twenty previously ... Cited by 2 - Related articles - All 11 versions
